New concerns about thalidomide

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Recently, the Food and Drug Administration (FDA) approved thalidomide for the treatment of the painful symptoms of erythema nodosum leprosum. This most recent FDA decision is a marked reversal to its previous rejection of this drug in the 1960s. The initial rejection by the FDA in the 1960s spared countless American children as thalidomide was shown to cause birth defects and miscarriages worldwide. The FDA's reputation as one of the finest consumer safety authorities was strengthened because of this decision. The recent approval of thalidomide by the FDA, with accompanying strict guidelines and monitoring procedures, has not only brought forth potential benefits, but also created new potential problems.

Original languageEnglish
Pages (from-to)125-128
Number of pages4
JournalObstetrics and gynecology
Volume99
Issue number1
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint Dive into the research topics of 'New concerns about thalidomide'. Together they form a unique fingerprint.

  • Cite this